Yu-Mi Lee1, Sang-Oh Lee2, Sang-Ho Choi2, Yang Soo Kim2, Jun Hee Woo2, Dae-Young Kim3, Jung-Hee Lee3, Je-Hwan Lee3, Kyoo-Hyung Lee3, Sung-Han Kim4. 1. Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Infectious Diseases, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea. 2. Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 3. Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 4. Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address: kimsunghanmd@hotmail.com.
Abstract
OBJECTIVE: There is little information on the efficacy of interferon-gamma-releasing assays for predicting subsequent active tuberculosis in hematopoietic stem cell transplant (HCT) recipients. METHODS: We prospectively enrolled adult patients admitted for allogeneic HCT during a 3-year period in an intermediate-tuberculosis-burden country. All the patients underwent QuantiFERON-TB In-Tube (QFT-TB) assay, while those enrolled during the first 2-year period also received the tuberculin skin test (TST). We observed the development of tuberculosis after HCT for additional 6-month. RESULTS: Of the 391 patients, 8 developed tuberculosis. Three of the 45 patients with positive QFT-TB results developed tuberculosis, while 5 of the 346 patients with negative or indeterminate QFT-TB outcomes developed tuberculosis (rate difference 2.7 per 100 person-years, P = 0.05). Of the 169 patients who underwent both TST and QFT-TB, 5 developed tuberculosis after HCT. None of the 19 patients with positive TST developed tuberculosis. Among the 150 patients with negative TST, there were 20 with positive QFT-TB and, of these, 3 developed tuberculosis, while 2 of the 130 patients with negative or indeterminate QFT-TB assays developed tuberculosis (rate difference 6.5 per 100 person-years, P = 0.004). CONCLUSION: Positive QFT-TB assay results predict subsequent development of tuberculosis in HCT recipients in whom latent tuberculosis cannot be detected by TST (NCT01021124).
OBJECTIVE: There is little information on the efficacy of interferon-gamma-releasing assays for predicting subsequent active tuberculosis in hematopoietic stem cell transplant (HCT) recipients. METHODS: We prospectively enrolled adult patients admitted for allogeneic HCT during a 3-year period in an intermediate-tuberculosis-burden country. All the patients underwent QuantiFERON-TB In-Tube (QFT-TB) assay, while those enrolled during the first 2-year period also received the tuberculin skin test (TST). We observed the development of tuberculosis after HCT for additional 6-month. RESULTS: Of the 391 patients, 8 developed tuberculosis. Three of the 45 patients with positive QFT-TB results developed tuberculosis, while 5 of the 346 patients with negative or indeterminate QFT-TB outcomes developed tuberculosis (rate difference 2.7 per 100 person-years, P = 0.05). Of the 169 patients who underwent both TST and QFT-TB, 5 developed tuberculosis after HCT. None of the 19 patients with positive TST developed tuberculosis. Among the 150 patients with negative TST, there were 20 with positive QFT-TB and, of these, 3 developed tuberculosis, while 2 of the 130 patients with negative or indeterminate QFT-TB assays developed tuberculosis (rate difference 6.5 per 100 person-years, P = 0.004). CONCLUSION: Positive QFT-TB assay results predict subsequent development of tuberculosis in HCT recipients in whom latent tuberculosis cannot be detected by TST (NCT01021124).
Authors: Guillermo Martín-Sánchez; Marta Drake-Pérez; José Luis Rodriguez; Lucrecia Yañez; Andrés Insunza; Carlos Richard Journal: Ecancermedicalscience Date: 2015-05-05
Authors: Shi Nae Yu; Jiwon Jung; Yong-Kyun Kim; Ju Young Lee; Sun-Mi Kim; Su Jin Park; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim Journal: Medicine (Baltimore) Date: 2015-07 Impact factor: 1.889
Authors: Andrew J Ullmann; Martin Schmidt-Hieber; Hartmut Bertz; Werner J Heinz; Michael Kiehl; William Krüger; Sabine Mousset; Stefan Neuburger; Silke Neumann; Olaf Penack; Gerda Silling; Jörg Janne Vehreschild; Hermann Einsele; Georg Maschmeyer Journal: Ann Hematol Date: 2016-06-24 Impact factor: 3.673